Skip to main content

Cancer

Cancer Research Institute

Clinical Trials

Showing 73-81 out of 131 results.
NCT05610163

THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

Icon for trial | A022104 THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN 
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This study is currently enrolling.

To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.To evaluate and co ...

NCT00736749

Umbrella Long-Term Follow-Up Protocol

Icon for trial | ALTE05N1 Umbrella Long-Term Follow-Up Protocol

This study is currently enrolling.

The overall goal of this study is to keep in contact with participants of COG clinical trials, so that up-to-date information will be available about these participants as they get older. This includes current name, contact, an ...

NCT06191796

XL092-009 A Phase 1b/2 Dose-Finding And Expansion Study Evaluating The Safety And Efficacy Of Xl092 Combined With Either AB521 OR AB521 Plus Nivolumab In Subjects With Advanced Clear Cell Renal Cell Carcinoma Or Other Advanced Solid Tumors

Icon for trial | XL092-009 XL092-009  A Phase 1b/2 Dose-Finding And Expansion Study Evaluating The Safety And Efficacy Of Xl092 Combined With Either AB521 OR AB521 Plus Nivolumab In Subjects With Advanced Clear Cell Renal Cell Carcinoma Or Other Advanced Solid Tumors

This study is currently enrolling.

To determine the recommended doses (RDs) of zanzalintinib and AB521 when administered in combination (doublet) in subjects with advanced solid tumors, and in combination plus nivolumab (triplet) in subjects with advanced ccRCC ...

NCT04137900

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma

Icon for trial | TAB004-01 A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid

The purpose of this study is to determine the side effects of TAB004 (investigational drug) when given alone or in combination with toripalimab (another investigational drug), to determine a reasonably safe amount (dose) of TAB ...

NCT03821935

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.

Icon for trial | M19-345 A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastati

The purpose of this study is to see if the study drug is safe and able to treat patients who have certain types of cancers, including solid tumors, triple negative breast cancer, pancreatic cancer, urothelial cancer, hepatocell ...